The ubiquitin-fold modifier 1 (UFM1)-system, a ubiquitin-like protein conjugation system, is involved in the development of breast cancer and several hereditary neurological syndromes. However, the molecular mechanisms of UFM1-related pathogenesis remain unclear. Here, we show that in the absence of UFSP2, a deconjugating enzyme for UFM1, ectopic expression of both UFL1 and UFBP1, which serve as the E3-ligase complex for the UFM1-system, dramatically increases UFM1-conjugate formation at the endoplasmic reticulum. Utilizing this system, we were able to attribute disease-related isoforms of UBA5, the E1 enzyme for UFM1, to decreased UFM1-conjugate formation. Our procedure allows the assessment of UFM1-conjugate formation in cells and the identification of UFM1-targets, both of which are needed to clarify the pathophysiological role of the UFM1-system.
Post-translational protein modifications by specific proteins give rise to functional conversion of target molecules, and thus they expand restricted genomic information and support diversity of biological process in eukaryotes. Among the variety of post-translational modifications, ubiquitination is the best-characterized protein modification system [1] . Ubiquitin is covalently linked as a chain or single molecule to lysine residues of proteins in an enzymatic cascade consisting of E1 (activating), E2 (conjugating), and E3 (ligating) enzymes. In the initial step, ubiquitin is activated by E1, which forms a high-energy thioester bond with ubiquitin in an ATP-dependent manner. The activated ubiquitin is then transferred to E2, forming similar thioester linkage. In most cases, E3 binds to both E2 and target proteins and ensures target specific ubiquitin-conjugation (ubiquitination) [1, 2] . The covalent modification of cellular proteins with ubiquitin mediates various cellular events including selective protein turnover through the 26S proteasome and autophagy [2, 3] . The covalent attachment of ubiquitin to target molecules can be reversed by deubiquitinases [4] , supporting the reversibility of ubiquitin system. During the past two decades, a series of ubiquitin-like modifiers (UBLs), which form covalent linkages to target protein(s) by an enzymatic cascade analogous to ubiquitination, have been identified [5] . Modification of intracellular proteins by UBLs is involved in protein localization and protein-protein and protein-DNA interactions, and thus in regulation of highly divergent cellular events. In fact, malfunction of protein modification by UBLs causes a wide variety of lifethreatening diseases [5] .
Among UBLs, ubiquitin-fold modifier 1 (UFM1) has been poorly characterized, and its biological function remains largely unknown. However, during the past decade, we identified all components involved in the UFM1-conjugation using mass spectrometric analysis and were able to characterize the UFM1-conjugating reaction: (a) UFM1 is synthesized as a precursor form and cleaved at the C terminus by the UFM1-specific protease, UFSP2. (b) An E1-like enzyme, UBA5, activates the mature UFM1. (c) The activated UFM1 is then transferred to an E2-like enzyme, UFC1. (d) UFM1 is covalently conjugated with cellular proteins by an E3-ligating enzyme, UFL1 (UFMylation). (e) UFBP1 is a substrate for UFM1, and UFMylated UFBP1 promotes the E3 ligase activity of UFL1. (f) The conjugates are cleaved by UFSP2, implying the reversibility of the UFM1-conjugating system [6] [7] [8] [9] [10] (Fig. 1) . The UFM1-system has an essential role in hematopoiesis in mice [11] [12] [13] , and plays a crucial role in estrogen receptor-a (ER a) transactivation, which assists development of ER a-positive breast cancer [10] . It has also been implicated in endoplasmic reticulum (ER) stress response [14] [15] [16] and autophagy [17, 18] . Very recently, we and another group independently showed that UBA5 mutations cause early-onset encephalopathies due to impaired UFM1-activation [19, 20] . It was also reported that compound heterozygous variants in UBA5 in a single family cause a childhood-onset neurological disease with ataxia [21] . A suggestive association of a UFSP2 variant with Beukes hip dysplasia was recently established [22] . While those findings shed light on the importance of UFM1-system in human health and diseases, the molecular mechanism by which the impairment of UFMylation causes human disorders remains unclear. A principal reason lies in the difficulty of detecting UFM1-conjugates, resulting in a low number of identified UFM1-substrates thus far. In this report, we established an easy method for assaying UFMylation in cells. This approach enables not only screening for target proteins and analysis of the UFM1-system but also evaluation of disease-related mutants of UFM1-system components.
Materials and methods

Cell culture
HEK293T and HeLa cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum, 5 U/mL penicillin, and 50 lg/mL streptomycin. To generate UFSP2-knockout cells, UFSP2 guide RNA designed by CRISPR Design tool (http://crispr.mit.edu/) was subcloned into pX330-U6-Chimeric_BB-CBh-hSpCas9 (Addgene #42230, Cambridge, MA, USA), a human codon-optimized SpCas9 and chimeric guide RNA expression plasmid. HEK293T or HeLa cells were cotransfected with the pX330 and pEGFP-C1 (#6084-1, Clontech Laboratories, Inc., Mountain View, CA, USA) vectors, and cultured for 2 days. Thereafter, the GFP-positive cells were sorted and expanded. Loss of UFSP2 was confirmed by heteroduplex mobility assay followed by immunoblot analysis with anti-UFSP2 antibody. UBA5 UFSP2-double knockout HEK293T cells [19] were used in this study.
Immunoblot analysis
Cells were lysed with ice-cold TNE buffer [10 mM Tris-Cl, pH 7.5, 1% Nonidet P-40, 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA), and protease inhibitors]. For purification of FLAG-6xHis-tagged proteins, cells were lysed by TNE without EDTA, and the lysate was centrifuged at 20 000 9 g for 10 min at 4°C to remove debris. Ni-NTA agarose (R90101; Life Technologies, Carlsbad, CA, USA) was added to the lysate, and the mixture was shaken under constant rotation for 30 min at 4°C and centrifuged at 1000 9 g for 2 min at 4°C. Denaturing binding buffer (8 M urea, 20 mM sodium phosphate, pH 7.8, and 500 mM NaCl) was added to the precipitates, and the mixture was rotated for 30 min at room temperature. The precipitates were washed three times with denaturing wash buffer (8 M urea, 20 mM sodium phosphate, pH 6.0, and 500 mM NaCl) and then three times with wash buffer (20 mM sodium phosphate, pH 6.0, and 500 mM NaCl). To elute proteins, elution buffer (20 mM sodium phosphate, pH 4.0, 500 mM NaCl, and 500 mM imidazole) was added to the complex, and the mixture was centrifuged at 10 000 9 g for 10 min at room temperature. The resulting supernatant was subjected to immunoblot analysis.
Microsome fraction was prepared using Microsome isolation kit (ab206995; Abcam, Cambridge, UK) according to the kit protocol. To prepare cytosolic fraction, the postmicrosomal fraction was centrifuged at 100 000 9 g for 1 h at 4°C. The resulting supernatant was used as cytosolic fraction.
Samples were separated using the NuPAGE system (Thermo Fisher, Waltham, MA, USA) on 12% Bis-Tris gels in MES/NuPAGE buffer, and transferred to polyvinylidene difluoride (PVDF) membranes. Antibodies against UFSP2 (ab185965; Abcam), UFM1 (ab109305; Abcam), and ACTIN (MAB1501R; Chemicon International, Inc., Billerica, MA, USA) were purchased from the indicated suppliers. Anti-UFL1 and UFBP1 polyclonal antibodies were described previously [9] .
Immunocytochemistry mCherry-UFM1DC2, GFP-UFL1, and UFBP1-FLAG or UFBP1 K267R -FLAG were coexpressed in UFSP2-deficient HeLa cells grown on coverslips. After incubation for 24 h, cells were fixed in 4% paraformaldehyde in PBS for 10 min, permeabilized with 0.1% digitonin in PBS for 5 min, blocked with 0.1% (w/v) gelatin (Sigma-Aldrich, St. Louis, MO, USA) in PBS for 30 min, and incubated overnight with primary antibody against UFBP1 or Calreticulin (PA3-900; ThermoFisher). After washing, cells were incubated with Alexa Fluor-conjugated goat anti-rabbit IgG secondary antibodies (A-21245; Life Technologies) for 60 min. Cells were imaged using a confocal laser-scanning microscope (FV1000; Olympus, Inc., Tokyo, Japan) with a UPlanSApo 1009 NA 1.40 oil objective lens. Z-projection stack images were acquired with z steps of 0.5 lm. Image contrast and brightness were adjusted using Photoshop CS4 (Adobe Systems, Inc., San Jose, CA, USA).
Results and discussion
Generation of UFSP2-knockout cells
In human, UFSP2 has been regarded as the sole enzyme that mediates both cleavage of C-terminal Ala of proUFM1 to produce mature UFM1 and deconjugation of UFM1 from target proteins [10] . Thus, it has been postulated that deletion of UFSP2 leads to decreased UFM1-conjugate formation and increase free UFM1 (i.e., proUFM1). To verify the role of UFSP2 in the UFM1-conjugation system, UFSP2 in HEK293T and HeLa cells was deleted by CRISPRCas9 technology ( Fig. 2A) . To our surprise, loss of UFSP2 in HEK293T cells caused prominent accumulation of two UFM1-conjugates and decrease of free UFM1, whereas UFM1-conjugates could hardly be detected in parental HEK293T cells ( Fig. 2A) . These results imply that UFM1-processing protease(s) other than UFSP2 participates in the generation of mature UFM1 and that UFSP2 primarily functions as a UFM1 deconjugating enzyme.
Effect of UFL1 on UFM1 conjugate formation in UFSP2 À/À HEK293T cells Next, we examined whether ectopic expression of UFL1, an E3-ligase for UFM1 (Fig. 1) , enhances UFM1-conjugate formation in UFSP2-deficient cells. FLAG-His-tagged UFM1DC2 and MYC-tagged UFL1 were expressed in parental and UFSP2-deficient HEK293T cells, followed by pull-down assay with Ni-NTA agarose under denaturing condition. FLAG-His-UFM1DC2 lacking the C-terminal Ser 84 and Cys 85 of proUFM1 is equivalent to mature UFM1 1-83 protein (Fig. 2B) . FLAG-His-UFM1DC3 lacking the C-terminal Gly 83 of mature UFM1 (i.e., deletion form of three residues from precursor UFM1 1-85 protein) was used as negative control (Fig. 2B) . As shown in Fig. 2C , the formation of UFM1 conjugates was markedly increased by overexpression of UFL1 in UFSP2 À/À cells, but not in parental HEK293T cells, and this increase was further enhanced by coexpression of UFBP1. On the other hand, expression of UFBP1 alone had no effect on the conjugation (Fig. 2C) . Similar results were obtained in UFSP2-knockout HeLa cells (Fig. S1A) . These results confirm that UFSP2 participates in a rapid deconjugation of UFM1 from target proteins. These results also indicate that the UFL1-UFBP1 complex is capable of promoting protein UFMylation in UFSP2-knockout cells.
UFMylation of UFBP1 in UFSP2-knockout HEK293T cells
We next examined the effect of UFSP2 deletion on UFMylation of a known target protein, UFBP1. When MYC-tagged UFM1DC2, UFL1, and FLAG-Histagged UFBP1 were expressed, UFMylated UFBP1 could be detected in UFSP2-deficient cells, but not parental HEK293T cells (Fig. 2D) . However, UFMylated UFBP1 could not be seen in UFSP2 À/À HEK293T cells, when UFBP1
K267R
, of which the UFM1 acceptor site Lys residue is substituted with Arg [9] , was expressed in place of wild-type UFBP1 (Fig. 2D) . UFMylated UFBP1 could neither be detected, when UFM1DC3 lacking C-terminal Gly residue essential for UFMylation was expressed (Fig. 2D) . Similar results were obtained in UFSP2-knockout HeLa cells (Fig. S1B) . These results clearly demonstrate that UFSP2 À/À cells are highly useful for detection of UFM1-conjugated proteins.
Localization of UFM1 in UFSP2-knockout HeLa cells
To determine the localization of UFM1 and its conjugates in UFSP2-deficient HeLa cells, mCherry-tagged UFM1DC2 was expressed with and without UFBP1-FLAG and/or GFP-UFL1. mCherry-UFM1 was distributed throughout the cell when it was expressed alone (Fig. 3A) . Expression of either UFL1 or UFBP1 (both of which are known to localize on the ER) showed little or no effect on mCherry-UFM1 localization ( Fig. S2) . By contrast, mCherry-UFM1DC2, but not mCherry-UFM1DC3, was evidently recruited to the ER when both UFBP1-FLAG and GFP-UFL1 were coexpressed (Fig. 3A) . In addition, UFMylation-deficient UFBP1
K267R
-FLAG could not support the recruitment of mCherry-UFM1DC2 to the ER (Fig. 3A) . The translocation of mCherry-UFM1DC2 to the ER was not observed in the case of parental HeLa cells even under coexpression of UFBP1-FLAG and GFP-UFL1 (Fig. S3) . These results strongly suggest that the signal of mCherry-UFM1DC2 detected on the ER represents UFMylated proteins including UFMylated UFBP1.
To confirm these findings biochemically, we carried out subcellular fractionation assays. When FLAG-His- À/À UFSP2 À/À HEK293T cells were transfected with the indicated plasmids. About 24 h after transfection, the microsome fraction was prepared as described in Materials and methods, and subjected to NuPAGE, followed by immunoblotting with the indicated antibodies. Data are representative of seven separate experiments. Bar graphs indicate the quantitative densitometric analyses of FLAG-UFM1-conjugation relative to the loaded protein amount (estimated by Ponceau-S Staining) and of FLAG-UFM1-UFBP1-MYC relative to the loaded protein amount, respectively. Statistic analysis was performed using an unpaired t test (Welch test). Bars represent the mean AE SE of seven separate experiments. *P < 0.05, **P < 0.01, and ***P < 0.001.
UFM1DC2, MYC-UFL1, and UFBP1-MYC were expressed in UFSP2-deficient HEK293T cells, UFM1 conjugates were significantly enriched in the microsome fraction as compared to those in the cytosolic fraction (Fig. 3B, top panel) . Moreover, UFMylated UFBP1 (UFBP1-MYC-UFM1) could be detected only in the microsome fraction (Fig. 3B, bottom panel) . However, the levels of UFM1 conjugates in both the microsome and cytosolic fractions were markedly decreased upon expression of FLAG-His-UFM1DC3 or UFBP1 K267R -MYC in place of their wild-type forms (Fig. 3B, top  panel) . In addition, UFMylated UFBP1 could not be seen in either fraction when the UFM1 lacking C-terminal Gly or the UFMylation-deficient UFBP1 was expressed (Fig. 3B, bottom panel) . Collectively, these results suggest that the UFL1-UFBP1 complex serves as an E3 ligase for UFM1 conjugation of cellular proteins on the ER and this process is largely dependent on UFM1 conjugation to UFBP1.
Assessment of UBA5 mutations using UBA5 UFSP2-double knockout cells
Recently, we and Bonneau's group have independently shown that compound heterozygote for a loss-of-function mutation on one allele and a p.Ala371Thr mutation on the other causes severe infantile-onset encephalopathy [19, 20] . We have also shown that the UBA5 A371T mutation suppresses the formation of UFMylated UFBP1 [19] . Heterozygotes with single loss-of-function allele do not show any disease symptom, implying that combination of functionally defect mutation with a lossof-function is crucial for the disease onset. In addition to the p.Ala371Thr mutation, Bonneau's group identified individuals from two families with biallelic compound heterozygous variants in UBA5, p.Met57Val, and p.Gly168Glu, and p.Val260Met and p.Asp389Tyr [20] (Fig. 4A and B) . These mutations, except for UBA5 D389Y , have decreased E1-activity (i.e., transfer activated UFM1 to the E2 enzyme UFC1 at reduced rates) [20] . Duan and colleagues reported that a family with two siblings with compound heterozygous variants in UBA5 (p.Lys310Glu and p.Arg246X) shows a childhood-onset neurological disease with ataxia as the primary symptom [21] (Fig. 4A,B) . However, the effect of these UBA5 mutations on UFM1 conjugation to target proteins remained unknown.
To determine whether the UBA5 mutations influence the formation of UFM1 conjugates, FLAG-His-UFM1DC2, MYC-UFL1, and UFBP1-MYC were expressed with wild-type UBA5 or one of the UBA5 mutants in UBA5 À/À UFSP2 À/À HEK293T cells. As previously reported [19] , complementation of wild-type UBA5 to the double knockout cells led to formation of UFM1 conjugates including UFMylated UFBP1 (Fig. 4C) . Remarkably, however, UBA5 G168E mutation led to a complete loss of the ability to generate UFM1 conjugates including UFMylated UFBP1 (Fig. 4C) . Although its allelic product UBA5 M57V was capable of generating UFM1 conjugates, it displayed reduced activity in formation of UFMylated UFBP1 compared to wild-type UBA5 (Fig. 4C) . Similarly, the level of UFM1-UFBP1 conjugate was decreased in the cells expressing UBA5 K310E , whose allele was paired with a loss-of-function mutant of UBA5 (p.Arg246X) in an affected patient (Fig. 4C) . These results well match with cases of compound heterozygotes for the hereditary encephalopathy reported previously (i.e., a lossof-function mutant in combination with a reduced enzymatic activity mutant) [17] . By contrast, both UBA5 V260M and UBA5 D389Y generated UFM1 conjugates comparable to wild-type UBA5, although its ability to form UFMylated UFBP1 was reduced (Fig. 4C) , raising possibilities that other factor(s), such as the destabilization of UBA5 mutant protein and monoallelic expression of UBA5 gene, is involved in the disease onset.
In conclusion, the strategy presented in this paper enables not only the assessment of UFM1-conjugate formation in cells but also identification of UFM1-targets, both of which are needed to clarify the pathophysiological role of the UFM1 system.
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